Chelonia Applied Science’s Post

🚀 Excited to share my latest article on "AI-Driven Drug Discovery: Accelerating Pharmaceutical Research"! 🧬💊 AI is revolutionizing the pharmaceutical industry by enhancing efficiency, accuracy, and cost-effectiveness in drug discovery. This article explores how AI is transforming various stages of drug development, including: 💉Target Identification and Validation: Leveraging AI to uncover novel drug targets. 💉Hit Identification: Using AI models to screen vast chemical libraries and predict compound interactions. 💉Lead Optimization: Generative AI designing new molecules with desired properties. 💉Preclinical Testing: Predicting pharmacokinetics and toxicity with machine learning. 💉Clinical Trials: Improving trial design, patient cohort identification, and real-time monitoring. With case studies from Insilico Medicine, BenevolentAI, and Atomwise, this article highlights real-world applications and the potential of AI to bring effective treatments to market faster. Discover how AI is driving a new era of rapid and cost-effective drug development. Read the full article here: https://lnkd.in/gVtP3UmY. #ArtificialIntelligence #DrugDiscovery #Pharmaceuticals #MachineLearning #HealthcareInnovation #AIinPharma

Pharma's R&D productivity crisis has been an ongoing concern. However, there's hope on the horizon! Dr. Suzanne Kurtzer Minton, PhD, Director of Content Strategy at Certara, discusses the world of biosimulation and its profound impact on streamlining the drug development process. Check out her latest blog to understand how this innovative approach is revolutionizing the pharmaceutical landscape. https://ow.ly/ctlc50Q34qi #DrugDevelopment #ClinicalDevelopment #Biosimulation #Ai #PharmaTechnology

New report shows AI drugs could nearly double pharma productivity. ◾ In a new report from Boston Consulting Group (BCG) published in the journal Drug Discovery Today, researchers analyzed pipeline data for AI biotechs and pharma partners who had entered 75 molecules into the clinic since 2015. ◾ With the exponential growth in AI drug discovery, the authors note that the next "coming wave" in AI drug discovery will be in the clinical trial stage. ◾ As of Dec. 2023, 24 AI molecules had completed Phase I trials, of which 21 were successful. This is an 80-90% success rate, far higher than historic averages of 40-55%. ◾ 10 molecules had completed Phase II, of which 4 were successful -- a 40% success rate that's in line with industry averages (30-40%), but it's worth noting that of the 6 programs discontinued, only 2 were due to negative outcome data, the others to shifts in business priorities. ◾ While the sample size is small, the implications are huge. As they write: "If we take, at face value, the success rates we observed for AI-discovered molecules in Phase I and II and assume that these hold in the future, and if we combine these with historic Phase III success rates, a striking picture emerges: the probability of a molecule succeeding across all clinical phases end-to-end would increase from 5–10% to ∼9–18%. This would represent almost a doubling of pharmaceutical R&D productivity overall." #ai #drugsdiscovery #biotech #pharma #productivity *Link to full report in comments

AI can revolutionize pharmaceutical R&D, specifically the early stages of target selection and drug discovery. This contributes to medical innovation and optimized use of resources which will benefit patients and healthcare systems. A growing number of pharmaceutical assets based on AI platform use have entered into clinical trials over the past years. Once the overall slowdown (especially 2023) in biotech/pharma funding and thereby initiation of new clinical trials reverts back, we expect more and more such assets to enter phase I and to thereby further fill this pipeline. - More accurate drug target identification AI accelerates drug target identification by analyzing vast biological data, revealing potential targets faster and with greater precision than traditional methods - More efficient drug selection AI enhances efficiency by predicting drug-target interactions, prioritizing compounds with higher therapeutic potential, and reducing trial-and-error in pre-clinical and clinical stages - Innovation and public health gains Leveraging AI in drug discovery optimizes resources, expedites the development process, and fosters innovation, ultimately advancing precision medicine and improving patient outcomes Roland Berger Belgium happily supports local and international Health players to navigate their most critical challenges. Please feel free to contact our experts: Grégoire Tondreau Astrid Böhlke Maarten Rabijns Michael Baur #RolandBerger #RBHealthBelgium #Innovation #Healthcare #Pharma

South Korea's Strategic Innovation in Healthcare South Korea has emerged as a global leader in leveraging AI to drive innovation in healthcare and drug discovery. Through strategic government initiatives and public-private partnerships, South Korea has cultivated a thriving ecosystem conducive to technological advancement in the life sciences sector. One notable success story is the collaboration between the South Korean government and leading pharmaceutical companies to establish AI-powered drug discovery platforms. By combining vast datasets, advanced algorithms, and high-performance computing resources, these platforms accelerate the identification and optimization of novel therapeutics, positioning South Korea at the forefront of pharmaceutical innovation.

Daiichi Sankyo and Depixus have announced a strategic partnership to accelerate the development of RNA-targeted drug discovery. This collaboration will provide a dedicated approach to discovering new treatments for a range of diseases, while leveraging existing technologies and platforms specialised in the study of RNA 🧬😊 Daiichi Sankyo brings stabilising expertise and pharmaceutical criteria to the partnership, enabling Depixus to reach their common goals faster. This knowledge, combined with Depixus' comprehensive clinical data insights and entire drug discovery process, will create completely novel opportunities for the development of treatments 🧰🤝 This partnership is a unique step forward in accelerating RNA-targeted drug discovery. By leveraging existing markets and technologies and creating a dedicated approach, this collaboration is sure to make a big impact in the field of chemical biology 🔬🤩 #DS9411 #RNA #collaboration

This is a great article about pharma industry trends from 2023 and what to watch for in 2024.

Can AI be the key to solving Pharma's R&D challenges? In her latest blog post, Suzanne Kurtzer Minton, PhD, Director of Content Strategy at Certara, explores the potential of biosimulation and AI to revolutionize pharmaceutical R&D. From drug discovery to clinical trials, these technologies are poised to accelerate the development of new treatments. Learn why Certara.AI is a game changer. https://ow.ly/AzhF50Q34TH #DrugDevelopment #ClinicalDevelopment #Biosimulation #Ai #PharmaTechnology

Excited to share my latest article on LinkedIn! 🚀 We explore how AI-driven chatbots, particularly ChatGPT, are revolutionizing drug delivery innovation in the pharmaceutical industry. From streamlining research processes to enhancing patient-centric approaches, ChatGPT is reshaping the landscape of drug development. Check out the full article to learn more about the transformative impact of AI in healthcare! #AI #DrugDelivery #Pharmaceuticals #Innovation https://lnkd.in/eyRkXJAW